You are reviewing medication options for a patient experiencing allergic conjunctivitis. Which class of medications would be best to consider?

Migraine prophylaxis is indicated in patients who experience frequent attacks, significant functional impairment, or poor quality of life despite effective abortive therapy. Preventive medications aim to reduce the frequency, severity, and duration of migraine episodes. In patients with comorbid conditions such as asthma, medication selection must avoid agents that may worsen respiratory function. Individualized therapy is essential to balance efficacy with safety.

Rationale:
A. Referral for ergotamine-based infusions is not appropriate for long-term migraine prevention. Ergotamine therapies are primarily used for acute or refractory migraine attacks, not routine prophylaxis. Additionally, infusion therapy is reserved for severe, treatment-resistant cases and would not be first-line for a stable outpatient with controlled abortive response using triptans.

B. Amitriptyline (Elavil) is an appropriate choice for migraine prevention in this patient. It is effective in reducing migraine frequency by modulating serotonin and norepinephrine pathways involved in pain transmission. It is also safe in patients with asthma, unlike beta-blockers, making it a suitable prophylactic option for MN’s clinical profile.

C. Propranolol (Inderal) is commonly used for migraine prophylaxis but should be avoided in patients with asthma. As a non-selective beta-blocker, it can cause bronchoconstriction by blocking beta-2 receptors in the lungs, potentially worsening asthma symptoms. Therefore, it is contraindicated in this patient despite its effectiveness for migraines.

D. Phenytoin (Dilantin) is not indicated for migraine prophylaxis. It is primarily used for seizure disorders and has no established role in preventing migraines. Its adverse effect profile, including gingival hyperplasia and neurologic toxicity, makes it inappropriate for this clinical scenario.

Uncomplicated urinary tract infections (UTIs) are common in healthy adolescent and adult females and are most often caused by Escherichia coli. First-line empiric treatment is selected based on likely organisms, local resistance patterns, patient allergies, and severity of illness. In an afebrile patient without recent antibiotic exposure or complicating factors, short-course oral therapy is usually sufficient. The goal is to effectively eradicate the infection while minimizing resistance and unnecessary broad-spectrum antibiotic use.

Rationale:
A. Nitrofurantoin (Macrobid) is a preferred first-line treatment for uncomplicated lower urinary tract infections. It concentrates well in the urine and is highly effective against common pathogens such as E. coli. It is especially appropriate in healthy, afebrile patients without signs of pyelonephritis because it provides targeted therapy with a lower risk of widespread antibiotic resistance.

B. Amoxicillin/Clavulanate (Augmentin) can be used for UTIs in some cases, but it is not usually the preferred first-line empiric option for uncomplicated cystitis. Resistance among common urinary pathogens is higher compared with nitrofurantoin, and broader-spectrum coverage may be unnecessary. It is more often reserved for cases where first-line agents are contraindicated or culture results indicate susceptibility.

C. Azithromycin (Zithromax) is not appropriate for routine treatment of uncomplicated UTIs because it has poor activity against the most common urinary pathogens, particularly E. coli. It is more commonly used for respiratory infections and certain sexually transmitted infections. Its pharmacologic profile does not make it effective as standard empiric therapy for cystitis.

D. Ciprofloxacin (Cipro) is effective against urinary pathogens but is generally not recommended as a first-line treatment for uncomplicated UTIs in young healthy patients. Fluoroquinolones are reserved for more complicated infections due to concerns about resistance and serious adverse effects such as tendon injury and central nervous system complications. Safer narrow-spectrum options are preferred first.